Stock upgrades and downgrades for 2Q 2022. Oppenheimer Initiated Rain Therapeutics (RAIN) at Outperform
Read More »Stock upgrades and downgrades January 2021
DA Davidson Keeps the Buy Rating on Apple and raised the Price Target to $167 Wedbush Morgan Securities Inc. have an Outperform rating on Alphabet A (GOOGL)
Read More »Bind Therapeutics BIND Price Targets
Bind Therapeutics BIND Price Targets: • Credit Suisse starts the shares at Outperform. Price target is $21. • Cowen initiates at Outperform with a $30 price target. • Stifel starts BIND at Buy. Price target is $20. • JMP initiates at Market Outperform. Price target is $30.
Read More »